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Ovarian epithelial carcinoma is the leading cause of death from
gynaecological cancers among women in the western world. It is
estimated that in 1999 approximately 25 000 women in the USA
will have been diagnosed with ovarian cancer and about 14 000
deaths will have occurred due to this malignancy (Landis et al,
1999). Over the period 1990–1994 nearly 20 000 deaths from
ovarian cancer were recorded in the UK (Levi et al, 1999). Most
patients with advanced epithelial ovarian cancer are presently
treated with cytoreductive surgery followed by combination
chemotherapy. However, the long-term outcome of such treatment
is disappointing and new therapeutic strategies must be explored.
Bombesin-like peptides, such as the gastrin-releasing peptide
(GRP), were initially reported as autocrine growth factors in the
development and progression of some human small cell lung
carcinomas (Cuttitta et al, 1985; Carney et al, 1987; Moody and
Cuttitta, 1993; Siegfried et al, 1994), but recent studies also
suggest an involvement of bombesin and GRP in the pathogenesis
of pancreatic, prostatic, breast and other cancers, such as malig-
nant glioblastomas (Bologna et al, 1989; Yano et al, 1992; Wang
et al, 1996; Schally and Comaru-Schally, 1997; Kiaris et al,
1999; Markwalder and Reubi, 1999). Specific receptors for
bombesin/GRP have been shown in various human cancers,
including prostatic and mammary, in human breast, prostatic and
pancreatic cancer lines, and in mouse mammary cancers
(Szepeshazi et al, 1992; 1997; Halmos et al, 1995; Wang et al,
1996; Schally and Comaru-Schally, 1997; Markwalder and Reubi,
1999; Sun et al, 1999). Recently, the expression of receptors for
bombesin-like peptides was demonstrated in human ovarian
cancer specimens and ovarian cancer cell lines SW-626, OV-1063
and UCI-107 (Schally and Comaru-Schally, 1997; Kim et al, 1998;
Sun et al, 1999). Until now, three subtypes of bombesin/GRP
receptors have been characterized in humans: bombesin receptor
subtype-1 (GRPR/BRS-1) which binds GRP with high affinity;
NMBR/BRS-2, which is preferentially activated by neuromedin
B; and BRS-3 (Spindel et al, 1993). BRS-3 is considered an
orphan receptor with an unknown natural ligand. Recently, a
fourth receptor subtype BRS-4 has been cloned and characterized
in amphibia and its existence in mammals was also postulated
(Nagalla et al, 1995). The peptides of bombesin/GRP family
induce cell proliferation by mechanisms that involve activation of
phosphatidylinositol, Ca2+ release, and stimulation of the expres-
sion of c-fos and c-jun mRNAs (Spindel et al, 1993; Draoui et al,
1995; Nagalla et al, 1995).
The findings that bombesin-like and gastrin-like peptides may
function as autocrine/paracrine growth factors in certain tumours
prompted the development of bombesin/GRP antagonists as potent
antitumour agents (Radulovic et al, 1991; Cai et al, 1994; Reile
et al, 1995; Schally and Comaru-Schally, 1997). Bombesin/GRP
antagonists, such as RC-3095 and RC-3940-II, synthesized in our
laboratory suppressed the growth of various tumours including
prostatic, breast, lung, pancreatic, gastric and malignant glio-
blastomas (Szepeshazi et al, 1992; 1997; Qin et al, 1994a; 1994b;
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Shirahige et al, 1994; Jungwirth et al, 1997a; 1997b; Koppan et al,
1998; Miyazaki et al, 1998; Kiaris et al, 1999). RC-3095 and RC-
3940-II differ at N-terminus and at C-terminal. RC-3095 contains
N-terminal D-Tpi and C-terminal Leu, and RC-3940-II has Hca at
N-terminus and Tac at C-terminus (Hca is desaminophenylalanine;
Tac is thiazolidine-4-carboxylic acid; Tpi is 2,3,4,9-tetrahydro-
1H-pyrido[3,4-b]indol-3-carboxylic acid). Due to their structural
differences, RC-3940-II has a more restricted conformation than
RC-3095 resulting in about 200 times higher binding affinity to
GRP receptor than RC-3095, as demonstrated by the displacement
of [125I-Tyr4]bombesin in Swiss 3T3 cells (Reile et al, 1995).
The receptors for luteinizing hormone-releasing hormone (LH-
RH) are also expressed by ovarian cancers (Yano et al, 1994;
Chegini et al, 1996; Emons et al, 1998). Our group has previously
demonstrated that chronic treatment with the LH-RH antagonist
Cetrorelix, but not LH-RH agonist triptorelin, can induce a signi-
ficant inhibition of growth of OV-1063 human epithelial ovarian
cancer xenografted into nude mice (Yano et al, 1994). Because
both LH-RH analogues cause a comparable suppression of the
pituitary-gonadal axis, it was suggested that the antitumour action
of Cetrorelix was exerted in part directly on LH-RH receptors in
tumours (Yano et al, 1994).
In the present study we evaluated the anti-tumour effects of two
bombesin/GRP antagonists, RC-3095 and RC-3940-II on the
growth of human epithelial ovarian cancer cell line OV-1063,
xenografted into nude mice. The results were compared to those
obtained with the LH-RH antagonist Cetrorelix. In an attempt to
elucidate the mechanism of action of bombesin/GRP antagonists,
we investigated the effect of GRP on the expression of c-jun and
c-fos mRNAs in OV-1063 cells cultured in vitro. The outcome of
treatment with RC-3940-II on the mRNA levels of c-jun and c-fos
was also evaluated in OV-1063 tumours xenografted into nude
mice.
MATERIALS AND METHODS
Peptides
Bombesin antagonist D-Tpi6, Leu13y[CH2NH]Leu14BN(6–14)
(RC-3095), originally synthesized in our laboratory by solid-phase
methods (Radulovic et al, 1991), was manufactured by ASTA
Medica (Frankfurt am Main, Germany) in the form of acetate salt,
D22213. The novel BN antagonist Hca6,Leu13y[CH2N]Tac14-BN
(6–14) (RC-3940-II) was synthesized by solid-phase methods and
purified in our laboratory (Cai et al, 1994; Reile et al, 1995). Hca
is desaminophenylalanine, Tac is thiazolidine-4-carboxylic acid,
and Tpi is 2,3,4,9-tetrahydro-LH-pyrido[3,4-b]indol-3-carboxylic
acid. Cetrorelix (SB-75), [Ac-D-Nal(2)1, D-Phe(4Cl)2, D-Pal(3)3,
D-Cit6,D- Ala10] LHRH, originally synthesized in this laboratory
(Bajusz et al, 1988), was obtained from ASTA Medica.
RC-3095 and RC-3940-II were dissolved in dimethyl
sulphoxide (DMSO) and diluted with 0.9% saline. The final
concentration of DMSO was 0.1%. Cetrorelix was dissolved in
distilled water containing 5% mannitol.
Cell lines and cell proliferation assays
Human ovarian cancer cell line OV-1063, and ES-2 were obtained
from American Type Culture Collection (Rockville, MD, USA).
UCI-107 human ovarian carcinoma cell line was kindly provided
by Dr A Manetta (University of California, Irvine, CA, USA).
OV-1063 and UCI-107 cells were maintained in Roswell Park
Memorial Institute 1640 (RPMI-1640) medium, and ES-2 cells in
McCoy 5A medium, all supplemented with 10% foetal bovine
serum (FBS), vitamins, antibiotics, and antimycotics as described
previously (Horowitz et al, 1985). Cells were cultured in T-75
Flasks (Corning Costar Corp., Cambridge, MA, USA) in a humid-
ified atmosphere of 5% CO2 and 95% air at 37°C and passed every
4–6 days using 0.25% trypsin-EDTA (Yano et al, 1994). For the
evaluation of the c-jun and c-fos mRNA levels, cells were cultured
for 18 h as described previously, except that the tissue culture
medium contained 2% FBS during the exposure to GRP or RC-
3940-II at 10–7 M for 1–5 h. The effect of RC-3940-II on the rate
of cell proliferation was evaluated by the crystal violet method as
described previously (Bernhardt et al, 1992). The results were
calculated as %T/C, where T = optical density of treated cultures
and C = optical density of untreated cultures.
Studies on tumorigenicity
OV-1063, ES-2 and UCI-107 cells were exposed in vitro to 10–6 M
RC-3940-II for 24 h. Subsequently, 2 ´ 105 cells per animal were
injected s.c. into the right flanks of nude mice and the period
during which palpable tumours, measuring about 15 mm3, devel-
oped was recorded. Animals were observed daily until tumours
were developed in all experimental animals.
Histological methods
Histological analyses were performed in OV-1063 tumours
xenografted into nude mice. Mitotic and apoptotic cells were
counted in tumour slides stained with haematoxylin-eosin as
described earlier (Szepeshazi et al, 1992) and their number per
1000 cells were accepted as the mitotic and apoptotic indices. For
the demonstration of the nucleolar organizer regions (NOR) in
tumour cell nuclei, the AgNOR method was used as described
previously (Szepeshazi et al, 1992).
Proliferating cell nuclear antigen (PCNA) was detected by
immunohistochemistry as follows. Sections from paraffin-
embedded tumour samples were placed on silanated slides,
dewaxed and rehydrated. Slides were immersed in distilled water
and heated in a domestic microwave oven for 2 ´ 5 min. All incu-
bations were performed at room temperature as follows: blocking
solution 3% bovine serum albumin for 30 min, monoclonal anti-
PCNA (Calbiochem, La Jolla, CA, USA), at 1:500 for 60 min,
biotinylated anti-mouse IgG (Sigma, St. Louis, MO, USA), 1:400
for 60 min and Extravidine-peroxidase (Sigma), 1:100 for 60 min.
The product was visualized by 3,3¢-diaminobenzidine (Sigma Fast
DAB). Sections were evaluated at areas showing the highest
positivity. The positive and negative nuclei were counted in three
microscopic areas each containing about 330 cells, and the
percentage ratio of positive cells to total cells was calculated.
Animals
Five to 6-week-old female athymic Ncr nu/nu nude mice were
obtained from Frederick Cancer Research facility of the National
Cancer Institute (Frederick, MD, USA). The mice were housed in
sterile cages under laminar flow hoods in a temperature-controlledroom with a 12-h dark schedule and were fed autoclaved chow and
water ad libitum. Their care was in accord with institutional ethical
guidelines for the welfare of animals.
Experimental protocol
Xenografts of OV-1063 cells were initiated by s.c. injection of 107
cells into the right flank of three nude mice. Tumours resulting
after 4 weeks were aseptically dissected and mechanically minced:
1m m 3 tumour pieces were transplanted subcutaneously by trocar
needle into the right flank of the mice. The tumour take rate was
nearly 90%. Two weeks after tumour transplantation and while
the tumours measured approximately 30–40 mm3, the mice were
divided into five experimental groups of seven animals each and
received the following treatment as s.c. injections: group 1 (control),
vehicle solution; group 2, RC-3095 at a dose of 20 mg per day;
group 3, RC-3940-II at a dose of 20 mg per day; group 4, RC-3940-
II at a dose of 10 mg per day; group 5, Cetrorelix (SB-75) at a dose
of 100 mg per day. The treatment was continued for 25 days. The
dose of the analogues was determined on the basis of previous
studies using different tumour models. Tumours were measured
once a week with a microcaliper and the volume was calculated by
the formula of length ´ width ´ height ´ 0.5236 (Tomayko and
Reynolds, 1989). At the end of the experiment, mice were anaestae-
tized with methoxyflurane (Metofane; Pitman-Moore, Mundelein,
IL, USA) and sacrificed by decapitation. Trunk blood was collected
and centrifuged at 1000 g for 30 min at 4°C and serum was stored at
–20°C until assayed. Body weights were recorded and various
organs were removed and weighed. Tumours were carefully
removed, cleaned and weighed. Tumour burden at the end of the
experiment was calculated as tumour weight (mg) per body weight
(g). Tumour pieces were stored at –80°C for molecular biology
analysis. All experiments were approved by the institutional ACUC
and the procedures were essentially in accordance with UKCCCR
guidelines (1998) for the welfare of animals in experimental
neoplasia.
RNA extraction
Total RNA was extracted from frozen tissue samples by using
RNAsol B (TEL-TEST Inc., Friendswood, TX, USA) according to
the manufacturer’s instructions. The RNA pellets were suspended
in 50 ml of 10 mM Tris, 1 mM EDTA buffer (pH 8.0) and quanti-
fied spectrophotometrically at 260 nm.
Reverse transcription-PCR (RT-PCR)
One microgram of total RNA was used in a test tube containing
10 mM Tris-HCI (pH 8.3), 50 mM KCI, 5 mM MgCI2, 1 mM of
each deoxynucleoside triphosphate, 1 U Rnase inhibitor, and 2.5 mM
random hexamer primers in a final volume of 19 ml of Rnase-free
deionized distilled water. The mixture was heated for 10 min at
65°C, quenched on ice, then 2.5 U of Moloney murine leukaemia
virus reverse transcriptase (Perkin-Elmer Corp., Norwalk, CT,
USA) in 1 ml was added, for a total reaction volume of 20 ml. The
mixture was incubated at room temperature for 10 min and then at
42°C for 1 h. The reaction was ended by heating at 95°C for 5 min
and quenching on ice. The PCR amplification of the cDNAs for
human glyceraldehyde-3-phosphate dehydrogenase (hGAPDH),
GRP, c-fos, c-jun, GRPR, BRS-3 and NMBR, was performed as
follows. One microlitre of the cDNA was amplified in a 50 ml solu-
tion containing 10 mM Tris.HCl (pH 8.3), 50 mM KCl, 1.7 mM
MgCl2, 200 mM of each dNTP, 2.5 Units Taq polymerase and
0.4 mM of each primer. The nucleotide sequence and the expected
PCR products for the oligonucleotide primers used are shown in
Table 1 (Kiaris et al, 1999; Sun and Schally, 1999). PCR consisted
of one cycle at 95°C for 3 min, 58°C for 1 min, and 72°C for 1 min
and subsequently 26 (hGAPDH), 30 (GRP), 29 (c-jun), 32 (c-fos),
cycles of 95°C for 35 s, 58°C for 40 s, and 72°C for 40 s by using a
Stratagene Robocycler 40 System. For the multiplex PCRs, the
cDNA for each target gene was amplified simultaneously with the
cDNA for hGAPDH, after supplementation of the primers for
hGAPDH at the appropriate cycle at 95°C. For the detection of
GRP, after the first round of PCR, 1 ml of the PCR product was
subjected to a second round of PCR consisting of 28 cycles. All
other parameters for the second round of PCR amplification were
similar to those described above for the first round of PCR amplifi-
cation. PCR amplification for GRPR, NMBR, and BRS-3 was
performed in Perkin Elmer DNA thermal cycler model 2400.
Samples were denatured at 94°C for 5 min and then subjected to 40
cycles comprised of 94°C for 1 min, 52°C for 1 min and 72°C for
1 min for GRPR and BRS-3 (1 ml products of the first PCR ampli-
fication were subjected to additional 30 cycles by using nested
primers); 40 cycles of 94°C for 30 s, 62°C for 30 s and 72°C for 30
s for NMBR, 25 cycles of 94°C for 30 s, 60°C for 30 s and 72°C for
30 s for hGAPDH, followed by a final extension at 72°C for 5 min.
In all RT-PCR amplifications negative controls were included, in
which H2O instead of RNA was used as template. Aliquots of PCR-
amplified product were resolved by electrophoresis on a 1.8%
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Table 1 Nucleotide sequence and size of the expected PCR products for oligonucleotide primers used for RT-PCR
Gene Sequence PCR product (bp)
hGAPDH 5¢-TCCTCTGACTTCAACAGCGACACC-3¢ 207
5¢-TCTCTCTTCCTCTTGTGCTCTTGG-3¢
GRP 5¢-TGCAAGAATTTGCTGGGTCTC-3¢ 485
5¢-TGTGAATGGTAACAGCTGGGG-3¢
c-fos 5¢-AAGGAGAATCCGAAGGGAAAGGAATAAGATGGCT-3¢ 612
5¢-AGACGAAGGAAGACGTGTAAGCAGTGCAGCT-3¢
c-jun 5¢-GCATGAGGAACCGCATCGCTGCCTCCAAGT-3¢ 409
5¢-GCGACCAAGTCCTTCCCACTCGTGCACACT-3¢
GRPR 5¢-ATTTGGCAGGATTGGCTGC-3¢ 158
5¢-TGAGGCAGATCTTCATCAG-3¢
BRS-3 5¢-GCTCTGTGGTTTCTAACG-3¢ 375
5¢-CTGCCTTGTATCTGTCAGC-3¢
NMBR 5¢-CGGACTTCTGCTGGAAAGGA-3¢ 484
5¢-GACGTCTGCATGTCCATGG-3¢agarose gel, stained with ethidium bromide, and visualized under
ultraviolet light. For quantitation of PCR-amplified products, a
scanning densitometer (model GS-700, Bio-Rad) was used,
coupled with the Bio-Rad personal analysis software.
Statistical analysis
Data are expressed as mean ± SE. Statistical analyses were
performed using Duncan’s new multiple range test (Steel and Torrie,
1976) and Student’s two-tailed t-test, one-way Anova and Dunnett’s
test. All P-values are based on two-sided hypothesis testing.
RESULTS
Effects of treatment with bombesin/GRP antagonists
RC-3095 and RC-3940-II and LH-RH antagonist
Cetrorelix on OV-1063 tumours in nude mice
After 25 days of treatment, the volume of OV-1063 tumours in the
two groups receiving the bombesin/GRP antagonist RC-3940-II,
was significantly reduced to 749.1 ± 141 mm3 (P < 0.05) for the
high-dose group (20 mg per day) and to 1102.5 ± 151 mm3
(P < 0.05) for the low-dose group (10 mg per day) as compared with
the controls (2820.4 ± 348.6 mm3), corresponding to decreases of
73.5% and 60.9% in tumour volume, respectively (Table 2, Figure
1). OV-1063 tumours in mice treated with the bombesin/GRP
antagonist RC-3095 measured 1481 ± 531.4 mm3, indicating a
47.7% decrease in tumour volume (P = 0.15). In the group treated
with LH-RH antagonist Cetrorelix, the tumour volume was reduced
to 1009.3 ± 249.2 mm3, corresponding to a 64.2% (P < 0.05)
decrease. The final tumour weights were also significantly dimin-
ished by 58.8% and 45.3% in the groups treated with the high-dose
(P < 0.05) and the low-dose of RC-3940-II (P < 0.05), respectively.
The tumour weight reduction in the group injected with Cetrorelix
was 52.4% (P < 0.05) and in the group receiving RC-3095, 30.9%
(not significant), as compared to controls (Table 2). A significant
(P < 0.01) decrease in the weight of ovaries was observed in the
group that received Cetrorelix. No significant differences in body
weights and the weights of various organs such as liver, kidneys,
and heart were observed between the control and the treated
animals.
Effect of bombesin/GRP antagonists RC-3095 and
RC-3940-II on the rate of cell proliferation
Cells cultured in vitro were exposed to bombesin/GRP antagonists
at various concentrations and their proliferation was monitored.
Using the crystal violet method, no significant effect was found on
the proliferation rate of OV-1063, ES-2 and UCI-107 ovarian
carcinoma cells after exposure to RC-3095 or RC-3940-II at
10–7–10–5M (data not shown).
Effect of bombesin/GRP antagonist RC-3940-II on
tumorigenicity of ovarian cancer cells
Before the injection into nude mice, OV-1063, UCI-107 and ES-2
ovarian carcinoma cells were exposed to RC-3940-II for 24 h at
10–6 M and the number of animals bearing palpable tumours was
recorded daily. As shown in Figure 2, the latency period for the
development of palpable tumours was extended by the pre-treatment
with RC-3940-II from 11.1 ± 1.0 days to 14.6 ± 1.0 days for OV-
1063 cells, from 7.5 ± 0.9 days to 13 ± 0.8 days for UCI-107 cells
and from 7.9 ± 1.5 days to 14 ± 1.0 days for ES-2 cells. These find-
ings indicated that the latency period for the establishment of
OV-1063, UCI-107 and ES-2 xenografts into nude mice was
significantly extended by 32% (P < 0.05 vs controls), 73%
(P < 0.001 vs controls) and 77% (P < 0.01 vs controls), respectively.
Bombesin/GRP antagonists for ovarian cancer 909
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Figure 1 Tumour volumes in athymic female nude mice bearing s.c.
transplanted OV-1063 human epithelial ovarian cancer cell line during
treatment with bombesin/GRP antagonists RC-3940-II at doses of 10 and
20 mg per animal and RC-3095 at a dose of 20 mg per animal, and LH-RH
antagonist Cetrorelix at a dose of 100 mg per animal administered by daily
s.c. injections. Vertical bars represent SE; *P < 0.05 vs control; aP = 0.15
Table 2 Effect of treatment with bombesin/GRP antagonists RC-3095 and RC-3940-II and LH-RH antagonist Cetrorelix on
tumour volume and weight in nude mice bearing xenografts of OV-1063 human epithelial ovarian cancer cell line
Treatment Intitial tumour Final tumour Tumour Tumour burden
volume (mm3) volume (mm3) weight (g) (mg g–1 bw)
Control 79.3 ± 17.4 2820.4 ± 348.6 4.88 ± 0.67 146.0 ± 19.0
RC-3095 81.0 ± 23.4 1481.4 ± 531.4 3.37 ± 0.87 107.0 ± 25.9
RC-3940-II/ 78.3 ± 12.8 749.1 ± 141.0a 2.01 ± 0.35a 72.4 ± 13.3a
20 mg ml–1
RC-3940-II/ 81.3 ± 11.2 1102.5 ± 151.0a 2.67 ± 0.41a 89.9 ± 13.7a
10 mg ml–1
Cetrorelix 86.5 ± 14.5 1009.3 ± 249.2a 2.32 ± 0.61a 76.6 ± 16.7a
a P < 0.05Histological findings
The results of the histological analysis are summarized in Table 3.
Bombesin/GRP antagonist RC-3940-II administered at 10 mg per
day or at 20 mg per day decreased significantly (P < 0.05) the
AgNOR numbers in the OV-1063 tumours as compared with the
controls, while RC-3095 administered at 20 mg per day did not
cause any significant reduction. PCNA expression was decreased
only by Cetrorelix and RC-3940-II (at doses of 20 mg per day)
(P < 0.05). Cetrorelix was also the only antagonistic analogue that
increased significantly (P < 0.05) the apoptotic index and the ratio
of apoptotic to mitotic indices in OV-1063 tumours, compared to
controls. PCNA indices showed significant correlation with
AgNOR counts (r = 0.556, P = 0.013), but not with mitotic
indices.
Investigation of the expression of mRNA for GRP and
bombesin receptor subtypes in OV-1063 human ovarian
epithelial cell carcinoma
The expression of mRNA for GRP and bombesin receptor
subtypes BRS-1 (GRPR), BRS-2 (NMBR) and BRS-3 in OV-1063
tumours was evaluated by RT-PCR. As shown in Figure 3, mRNA
for GRPR, NMBR and BRS-3 was detected in OV-1063 tumours,
but no mRNA for the GRP ligand could be found. To confirm the
absence of expression of mRNA for GRP, PCR products were
subjected to a second round of PCR amplification which was again
negative for the expected 485 bp band (Figure 4).
Effect of GRP and bombesin/GRP antagonist RC-3940-II
on mRNA expression of c-jun and c-fos oncogenes in
vitro and in vivo
In an attempt to investigate further the mechanism of anti-tumour
action of bombesin/GRP antagonists, we studied the role of
GRP(14–27) on the expression of mRNA for c-jun and c-fos onco-
genes, in vitro. The mRNA levels of c-jun and c-fos oncogenes
were assessed by RT-PCR after exposure of OV-1063 cells
cultured in vitro to 10–7 M GRP(14–27) for 1 h, 3 h and 5 h. As
shown in Figure 5, the maximal stimulation of c-jun mRNA levels,
about 436% vs basal, was observed 1 h after the exposure to
GRP(14–27), while the greatest increase in c-fos mRNA levels,
about 169% vs basal, was obtained after 5 h incubation with
GRP(14–27). The stimulation of mRNA for c-jun and c-fos by
GRP(14–27) was suppressed in the presence of 10–7 M
bombesin/GRP antagonist RC-3940-II. In vivo, the treatment of
mice bearing OV-1063 xenografts with RC-3940-II at a dose of
20 mg per day resulted in a significant decrease of 43% (P < 0.05)
and 45% (P < 0.05) in the mRNA levels for c-jun and c-fos
oncogenes respectively, while RC-3040-II at 10 mg per day had no
effect (Figure 6).
DISCUSSION
The present study shows for the first time that an antagonist of
bombesin/GRP, RC-3940-II, can significantly inhibit the growth
of OV-1063 human ovarian epithelial cancers xenografted into
nude mice when administered at doses of 10 mg and 20 mg per day.
The anti-tumour action of RC-3940-II is in agreement with the
decrease in the expression of PCNA and AgNOR numbers in OV-
1063 tumours xenografted into nude mice. PCNA and AgNOR are
910 I Chatzistamou et al
British Journal of Cancer (2000) 83(7), 906–913 © 2000 Cancer Research Campaign
Control
RC-3940-II
0
2
4
6
8
10
0 1 01 52 0
OV-1063
A
M
i
c
e
 
f
r
e
e
 
o
f
 
t
u
m
o
u
r
s
Time (days)
12
10
8
6
4
2
0
0 5 10 15 20
Control
RC-3940-II
Time (days)
ES-2
M
i
c
e
 
f
r
e
e
 
o
f
 
t
u
m
o
u
r
s
B
Control
RC-3940-II
0
05 1 0
Time (days)
15 20
2
4
6
8
10
12
M
i
c
e
 
f
r
e
e
 
o
f
 
t
u
m
o
u
r
s
UCI-107
C
Figure 2 Effect of bombesin/GRP antagonist RC3940-II on the
tumorigenicity of OV-1063 (A), ES-2 (B) and UCI-107 (C) ovarian carcinoma
cells. Cells were exposed in vitro to RC-3940-II at 10–6 M for 24 h and
subsequently injected s.c. into nude mice at 2 ´ 105 cells per animal. The
number of the tumour-bearing animals was recorded daily until all animals
developed palpable tumoursBombesin/GRP antagonists for ovarian cancer 911
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markers of cell proliferation and their expression is increased in
highly proliferative tissues. RC-3940-II also extended signifi-
cantly the latency period for the development of palpable tumours
in OV-1063, ES-2 and UCI-107 human ovarian carcinoma cells.
This finding was most likely due to the direct effect on tumori-
genicity and not to the cytotoxicity of bombesin/GRP antagonists
on these cells, because exposure of OV-1063, ES-2 and UCI-107
cells cultured in vitro to RC-3940-II had no effect on the rate of
cell proliferation. Another antagonist of bombesin/GRP, RC-3095,
previously developed in our laboratory, was less potent than RC-
3940-II in inhibiting the growth of OV-1063 tumours. The anti-
tumour effects of bombesin/GRP antagonists RC-3095 and
RC-3940-II were also compared with the effects of LH-RH antag-
onist Cetrorelix, which has been previously shown to inhibit the
proliferation of this tumour (Yano et al, 1994). Our results showed
that RC-3940-II was marginally, but not significantly, more potent
than Cetrorelix in inhibiting OV-1063 tumour growth. Treatment
with Cetrorelix significantly enhanced apoptosis and increased the
ratio of apoptotic to mitotic indices, which is in agreement with
previous findings on the regulation of apoptosis by LH-RH
analogues. That only Cetrorelix, and not RC-3940-II, induced
apoptosis in OV-1063 tumours, while both significantly inhibited
tumour growth to similar levels, is probably due to differences in
the mechanism of anti-tumour action between these antagonists.
This is also supported by previous findings that co-administration
of Cetrorelix and bombesin/GRP antagonists produces additive
effects on inhibition of tumour growth (Yano et al 1993; Jungwirth
et al 1997a; 1997b; 1998).
In an attempt to investigate the mechanism of action of
bombesin/GRP antagonists, we tested the effect of GRP(14–27) on
the expression of mRNA for c-jun and c-fos oncogenes, which are
regulated by the bombesin-like peptides in small cell lung carci-
nomas and malignant glioblastomas (Draoui et al, 1995; Kiaris et
Table 3 Effect of treatment with bombesin/GRP antagonists RC-3095 and RC-3940-II and LH–RH antagonist
Cetrorelix on various histological parameters of OV-1063 human ovarian carcinomas xenografted into nude mice
Groups Mitotic index Apoptotic Ratio PCNA index
index apoptotic: AgNORs per (%)
mitotic indices cell (n)
Control 14.0 ± 2.9 3.4 ± 0.4 0.29 ± 0.08 6.65 ± 0.17 89.1 ± 0.8
RC-3940-II/ 12.3 ± 1.3 4.5 ± 0.9 0.40 ± 0.13 5.85 ± 0.19a 83.1 ± 0.7a
20 mg
RC-3940-II/ 7.9 ± 0.7 5.6 ± 0.7 0.72 ± 0.06 5.93 ± 0.18a 85.3 ± 1.4
10 mg
RC-3095 14.5 ± 0.9 4.3 ± 0.7 0.30 ± 0.06 6.00 ± 0.06 86.7 ± 1.0
SB-75 12.5 ± 1.7 10.4 ± 1.3a 0.90 ± 0.21a 5.95 ± 0.13a 84.8 ± 0.7a
Values are means ± SE. aP < 0.05 vs control
GRPR
NMBR
BRS-3
GAPDH 
MN      1    2   3   4   5   6   7   8 
Figure 3 Expression of bombesin receptor subtypes in OV-1063 human
ovarian cancers. Lanes 1, 2 = control groups; lanes 3,4 = groups treated with
RC-3940-II (20 mg per day); lanes 5, 6 = groups treated with RC-3940-II
(10 mg per day); lane 7, 8 = groups treated with RC-3095; M = DNA
molecular marker; N = negative control
M                   1                     2                 3
500 bp-
Figure 4 Expression of mRNA for GRP ligand. Lane 1 = positive control
(RNA isolated from NCI-H-69 small cell lung carcinoma); lane 2 = RNA
isolated from OV-1063 human ovarian epithelial cancer cell line; lane 3 =
negative control
300 bp-
400 bp-
M      1       2     3       4      5      6       7     8      9
-c-jun
-hGAPDH
-c-fos
-hGAPDH
Figure 5 Expression of c-jun and c-fos mRNA in OV-1063 human ovarian
epithelial cancer cell line. Total RNA was extracted from cells cultured in
vitro, and c-jun and hGAPDH as well as c-fos and hGAPDH were co-
amplified by multiplex RT-PCR and electrophoresed on 2% agarose. Each
RT-PCR reaction was repeated at least three times and similar results were
obtained. Lane 1 = expression of c-jun and c-fos mRNA in cells without pre-
treatment; lanes 2, 4, 6 = expression of c-jun and c-fos in cells treated with
10–7 MGRP(14–27) for 1 h, 3 h, and 5 h; lanes 3, 5, 7 = expression of c-jun
and c-fos mRNA in cells treated with a mixture of 10–7 M RC-3940-II and
10–7 M GRP(14–27); lane 8 = expression of c-jun and c-fos in cells treated
with RC-3940-II alone; lane 9 = negative control; M = DNA molecular size marker912 I Chatzistamou et al
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al, 1999). The exposure of OV-1063 cells cultured in vitro to
GRP(14–27) resulted in a stimulation of mRNAs for c-jun and c-
fos oncogenes. The stimulation was maximal at 1 h for c-jun and at
5 h for c-fos, while prolonged exposure to GRP(14–27) resulted in
a lesser augmentation of the mRNA for these oncogenes. In OV-
1063 cells cultured in vitro, the stimulation with GRP(14–27)
caused a greater induction of mRNA expression for c-jun than for
c-fos, in contrast to previous findings in SCLC (Draoui et al, 1995)
and malignant glioblastomas (Kiaris et al, 1999). Considering that
in all the three tumours GRPR/BRS-1 is the main receptor that
mediates the proliferative effects of GRP(14–27), one might
postulate that other factors acting downstream of each receptor
modify the signal initiated by the ligand–receptor interaction,
resulting in specific effects on c-jun or c-fos observed in each cell
line. Bombesin/GRP antagonist RC-3940-II blocks the stimulatory
action of GRP on c-jun and c-fos mRNAs, while the exposure of
OV-1063 cells in vitro to RC-3940-II alone does not affect the
mRNA levels of these oncogenes, indicating the absence of
any intrinsic GRP activity in this antagonistic analogue of
bombesin/GRP. This is in agreement with the finding that mRNA
for GRP is not produced by OV-1063 cells and thus, the specific
bombesin/GRP antagonist RC-3940-II, when added alone to the
culture medium, has no effect in the regulation of c-jun and c-fos
oncogenes, and the rate of cell proliferation. The detection of
mRNA for the GRP ligand was performed using primers that span
the common region of the prepro-GRP to the 3¢-untranslated
region of the message (Siegfried et al, 1994). Although the detec-
tion of the mRNA for GRP by more sensitive methods such as
nested PCR and/or Southern blot hybridization cannot be
excluded, the autocrine stimulation of this tumour by GRP might
be much less important physiologically than paracrine stimulation.
In vivo, the levels of mRNA for c-jun and c-fos oncogenes
decreased significantly in tumours of mice receiving RC-3940-II,
which is likely due to the blockade of the endogenously produced
mouse-derived GRP, since mRNA for GRP could not be detected
in OV-1063 cells cultured in vitro. RC-3940-II administered at
20 mg per day but not at 10 mg per day inhibited significantly the
levels of mRNA for c-fos and c-jun oncogenes in vivo. This is
interesting because RC-3940-II, at both concentrations, produced
significant inhibition of tumour growth. This finding probably
indicates that higher levels of RC-3940-II are required for the
suppression of c-jun and c-fos mRNA expression, than for inhibi-
tion of tumour growth.
The exact mechanism by which GRP stimulates the expression
of c-jun and c-fos oncogenes is not completely understood. It has
been shown that bombesin/GRP-like peptides stimulate phospha-
tidylinositol and Ca2+ release (Spindel et al, 1993; Draoui et al,
1995), while the antagonistic analogues of bombesin/GRP down-
regulate the receptor for epidermal growth factor (Halmos et al,
1997) and inhibit the phosphorylation responses induced by
bombesin-like peptides (Liebow et al, 1994). It is possible that the
cascade of intracellular events initiated by the binding of
bombesin/GRP-like peptides to specific membrane receptors
results in the induction of c-jun and c-fos oncogenes. The products
of c-jun and c-fos oncogenes form the AP-1 transcription factor,
which in turn evokes the expression of genes with AP-1 inducible
elements (Halazonetis et al, 1988). The overexpression of the
AP-1 transcription factor is a common alteration detected in
various cancers. Thus, the association of the anti-tumour activity
of bombesin/GRP antagonists with a downregulation of c-jun and
c-fos oncogenes and presumably the AP-1 levels would not be
unexpected.
In summary, our results indicate that GRP is implicated in the
pathogenesis of OV-1063 ovarian epithelial cell carcinoma and its
mechanisms of action appears to involve the c-jun and c-fos onco-
genes. Antagonistic analogues of bombesin/GRP could be consid-
ered for the treatment of ovarian epithelial cancers that depend on
the production of bombesin-like peptides.
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